热门资讯> 正文
Viking发布VK 2735在糖尿病前期、代谢综合征中的新数据
2025-11-07 00:59
- Viking Therapeutics (VKTX) said that an analysis of phase 2 data on an injectable version of its GLP-1/GIP receptor agonist VK2735 showed positive improvements in prediabetes and metabolic syndrome.
- The analysis of the 13-week VENTURE trial found that at the end of it, 78% of patients treated with the drug who were prediabetic at baseline had successfully shifted to normal glycemic status. The figure was 29% for those on placebo.
- Also, 68% of those receiving VK2735 who were considered having megtabolic syndrome at the outset no longer did, compared to 38% on placebo.
- The subcutaneous version of VK2735 is currently in phase 3 for obesity. A pill version for the same indication is in phase 2.
More on Viking Therapeutics
- Sell Novo Nordisk And Buy Viking Therapeutics
- Viking Therapeutics: A Look At The Catalysts Ahead
- Viking Therapeutics Q3 Earnings: What We Learned (And Why We Should Keep Faith)
- Viking Therapeutics outlines completion of VANQUISH-1 enrollment by year-end while advancing novel VK2735 maintenance dosing study
- Viking sees enrollment in late-stage trial for oral obesity pill completed in Q4
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
